M&A Deal Summary

Celltrion Acquires iQone

On November 14, 2024, Celltrion acquired life science company iQone

Acquisition Highlights
  • This is Celltrion’s 2nd transaction in the Life Science sector.
  • This is Celltrion’s 1st transaction in Switzerland.

M&A Deal Summary
Date 2024-11-14
Target iQone
Sector Life Science
Buyer(s) Celltrion
Deal Type Add-on Acquisition

Target

iQone

Versoix, Switzerland
iQone is a specialty pharmaceutical company focused on distribution, sales, and marketing. iQone was founded in 2013 and is based in Versoix, Switzerland.

Search 201,157 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Celltrion

Incheon, South Korea
Category Company
Founded 2002
Sector Life Science
Employees2,391
Revenue 2.18T KRW (2023)
DESCRIPTION

Celltrion is a biopharmaceutical company specializing in the development of “biosimilars” for monoclonal antibody drugs. Celltrion provides biosimilars for auto-immune diseases and various cancers; generic pharmaceuticals; and covid-19 test kits. Celltrion was incorporated in 2002 and is based in Incheon, South Korea.

DEAL STATS #
Overall 2 of 2
Sector (Life Science) 2 of 2
Type (Add-on Acquisition) 1 of 1
Country (Switzerland) 1 of 1
Year (2024) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2020-11-30 Takeda Pharmaceutical - Primary Care Product Assets

Osaka, Japan

Takeda Pharmaceutical Co. Ltd. - Primary Care 18 products include prescription medicines such as Nesina (diabetes), Actos (diabetes), and Edarbi (hypertension) which were developed for the global market, as well as OTC (Over-the-counter) products well known to consumers such as Whituben (cold remedy). Nesina and Edarbi.

Buy $278M
Mergr

Product

Company

Legal